Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

World Health Organization Grants Prequalification to Prevenar 13*, Pfizer’s 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children

August 23, 2010 By Bio-Medicine.Org

NEW YORK, Aug. 23 /PRNewswire-FirstCall/ — The World Health
Organization (WHO) has granted prequalification to Prevenar 13*
(Pneumococcal polysaccharide conjugate vaccine [13-valent,
adsorbed])for active immunization of infants and children from 6
weeks through five years of age against invasive disease, pneumonia
and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4,
5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in the
vaccine. WHO prequalification allows for the procurement of
Prevenar 13 by United Nations agencies, including the United
Nations Children’s Fund (UNICEF), governments and other
organizations for use in national immunization programs. The
prequalification is for global use of the vaccine in a single-dose
vial.

(Logo:
http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo:
http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

“We are pleased to receive WHO prequalification as recognition
that Prevenar 13 meets the organization’s high standards for
quality,” says Emilio Emini, Ph.D., chief scientific officer,
Vaccine Research, Pfizer. “This is an important step towards our
goal of making Prevenar 13, which offers the broadest serotype
coverage of any pneumococcal conjugate vaccine, available to
infants and young children globally.”

In March 2010, Pfizer entered into a 10-year Provisional Supply
Agreement to provide Prevenar 13 to infants and young children in
the world’s poorest countries under the terms of the Advance Market
Commitment (AMC) for pneumococcal disease, an innovative program
piloted by the GAVI Alliance. In order to participate in the AMC
program, vaccines must receive WHO prequalification.

WHO’s prequalification program aims to make quality, priority
medicines available for the benefit of those in need. The WHO
prequalification process applies unified standards of acceptable
quality, safety and efficacy to vaccines and other medicinal
products.

To meet the gr

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech